NCT02583464View on ClinicalTrials.gov

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Acquired Immunodeficiency Syndrome
Interventions
DRUG

Tenofovir disoproxil fumarate and emtricitabine

Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

Trial Locations (1)

C1417AZE

Laboratorio Elea SACIFyA, Capital Federal

Sponsors
All Listed Sponsors
lead

Laboratorio Elea Phoenix S.A.

INDUSTRY